Jiajia Wang

Jiajia Wang

Auto-generated profile, based on publicly available information

Jiajia Wang

Henan University of Chinese Medicine, Zhengzhou, People’s Republic of China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2024 in BMC Public Health
Verified
Journal Article
Open access
PDF file
LWLu Wang
Lu Wang
JWJiajia Wang
Jiajia Wang
GZGuixiang Zhao
Guixiang Zhao
JLJiansheng Li
Jiansheng Li
Bronchiectasis, once considered an orphan disease, is receiving attention globally owing to its increasing prevalence, healthcare burden, and associated morbidity. However, the prevalence of bronchiectasis is unclear. This meta-analysis estimates the prevalence of bronchiectasis in adults, providing a valuable reference for future research. PubMed, Embase, Cochrane Library, and Web of Science databases were searched from inception to May 31, 2024 for studies reporting the prevalence of bronchiectasis. Study selection, data extraction, and overall analysis of risk of the retrieved studies were conducted independently by two authors. The tool for assessing the risk of bias in prevalence studies was used to evaluate overall risk. Stata software (version 15.1) was used to performed the meta-analysis. Subgroup and sensitivity analyses were conducted to identify the source of heterogeneity. Funnel plots combined with Egger’s test were used to detect publication bias. The pooled prevalence of bronchiectasis in adults from 15 studies covering 437,851,478 individuals was 680 per 100,000 (95% CI: 634–727 per 100,000). Subgroup analysis showed that the prevalence of bronchiectasis in the United States, Korea, and China was 478 per 100,000 (95% CI: 367–588 per 100,000), 886 per 100,000 (95% CI: 778–993 per 100,000), and 759 per 100,000 (95% CI: 35–2399 per 100,000), respectively; 467 per 100,000 (95% CI: 416–518 per 100,000) in males and 535 per 100,000 (95% CI: 477–592 per 100,000) in females; 3958 per 100,000 (95% CI: 117–12637 per 100,000), 4677 per 100,000 (95% CI: 427–8928 per 100,000), and 3630 per 100,000 (95% CI: 158–7103 per 100,000) among never-smokers, ever-smokers, and current smokers, respectively; 430 per 100,000 (95% CI: 411–450 per 100,000), 380 per 100,000 (95% CI: 374–386 per 100,000), and 351 per 100,000 (95% CI: 342–360 per 100,000) among individuals with body mass index<18.5, 18.5–24.9, and ≥ 25, respectively. Sixteen comorbidities were evaluated in patients with bronchiectasis, revealing a high rate. Bronchiectasis is not a rare disease and requires more attention from scientific researchers. The protocol for this review was registered with PROSPERO: CRD42023409216. Registered 26 June 2023.

15 December 2015 in MedChemComm
Verified
Journal Article
Closed access
PDF file
JWJiajia Wang
Jiajia Wang
XWXiaomin Wang
Xiaomin Wang
YZYunyan Zhao
Yunyan Zhao
XMXiaoyao Ma
Xiaoyao Ma
YWYue Wan
Yue Wan
WZWei Zhao
Wei Zhao
D-Gluconhydroximo-1,5-lactam and its oxime-substituted derivatives were prepared and assessed for inhibition and pharmacological chaperone (PC) activities in Gaucher disease cell lines derived from N370S. The most active compound, O-(D-glucopyranosylidene) amino-Z-N-dodecylcarbamate (38), gave a nearly 2.0-fold increase in N370S β-GCase activity at 12.5 μM with no inhibition to other commercially available glucosidases. Docking studies of ligand–enzyme interactions have also been conducted to account for the results of enzyme activity increase. All these results demonstrate that compound 38 is a promising PC for the treatment of GD.

2 January 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MLMengjuan Liu
Mengjuan Liu
JWJiajia Wang
Jiajia Wang
LWLu Wang
Lu Wang
XZXinyi Zhang
Xinyi Zhang
RHRuiyu Hao
Ruiyu Hao
JLJiansheng Li
Jiansheng Li
Background: With increasing attention to core outcome sets (COS), the number of studies on COS for respiratory diseases (COS-RD) is on the rise. However, the methodological quality is still unclear. Therefore, we conducted a study to assess the methodological quality of studies on COS-RD. Methods: PubMed, Embase, Cochrane Library, and Web of Science were searched for study protocols or original studies on COS-RD about adults, from their inception to February 23, 2024. The COMET database and Chinese databases (including China National Knowledge Infrastructure, Wanfang Data, Chongqing VIP database, and China Biology Medicine) were also searched as a supplement. Two researchers independently screened the literature, extracted the data, and assessed the methodological quality of included studies using the Core Outcome Set-STAndardised Protocol (COS-STAP) statement, the Core Outcome Set-STAndards for Development (COS-STAD) recommendations, and the Core Outcome Set-STAndards for Reporting (COS-STAR) statement. Results: A total of 27 articles (five study protocols and 22 original studies, 26 studies) were included in this study. For the assessment of study protocols using the COS-STAP statement, the item with the lowest complete reporting rate was "missing data" (Item 9, 40.0%), while "description how outcomes may be dropped/combined, with reasons" (Item 5b, 60.0%) and "dissemination" (Item 11, 60.0%) had relatively low complete reporting rates. For the assessment of original studies using the COS-STAD recommendations, the item with the highest non-reporting rate was "care was taken to avoid ambiguity of language used in the list of outcomes" (Item 11, 45.5%), while "the population(s) covered by COS" (Item 3, 31.8%) and "the intervention(s) covered by COS" (Item 4, 31.8%) had relatively high non-reporting rate. When using the COS-STAR statement to assess the original studies, the item with the lowest complete reporting rate was "protocol deviations" (Item 11, 13.6%), while “describe how outcomes were dropped/combined, with reasons (if applicable)” (Item 6b, 36.4%), "participants" (Item 5, 40.9%), "ethics and consent" (Item 10, 54.5%), "protocol/registry entry" (Item 14, 63.6%), and “outcome scoring” (Item 8, 63.6%) had relatively low complete reporting rates. Conclusion: The methodological quality of studies on COS-RD needs to be further improved. The appropriate use of aforementioned international reporting standards can advance the methodological quality and reporting transparency of studies on COS-RD.

10 August 2026 in Cost Effectiveness and Resource Allocation
Verified
Journal Article
Open access
PDF file
YXYang Xie
Yang Xie
WHWenqing He
Wenqing He
Hejia WanHejia Wan
Hejia Wan
RZRuifang Zhou
Ruifang Zhou
JWJiaJia Wang
JiaJia Wang
JLJiansheng Li
Jiansheng Li
Objectives: To evaluate, from a Chinese healthcare system perspective, the cost-utility of three treatment strategies (Western medicine, Traditional Chinese Medicine [TCM], and combined therapy) for stable chronic obstructive pulmonary disease (COPD) using a discrete event simulation (DES) model parameterized with clinical trial data. Methods: A DES model was developed for stable COPD patients (aged 18–80 years) from a Chinese healthcare system perspective. The model incorporated 24 baseline variables, six intermediate outcomes (FEV1, 6MWD, dyspnea, cough, sputum, COPD-PRO), and acute exacerbation as the final outcome. Multilevel mixed-effects models and Weibull regression updated these longitudinal outcomes every three months over a 2-year time horizon. Health outcomes were measured as quality-adjusted life years (QALYs), the primary outcome of the economic evaluation. Costs were estimated in 2013 RMB and adjusted to 2022 values using the China Consumer Price Index (CPI). Results: In the three-month base-case analysis, patients with COPD showed a mean 6.8 m increase in six-minute walk distance (6MWD), 0.25 fewer acute exacerbations, and improved symptom scores. The mean two-year total cost was 12,726.18 RMB. Cost-utility ratios (CURs) were 5,066.79, 4,477.09, and 4,540.93 RMB/QALY for the Western medicine, TCM, and combined therapy groups, respectively. Compared with the TCM group, the combined therapy group incurred an additional 448 RMB and gained 0.060 additional QALYs, yielding an incremental cost-utility ratio (ICUR) of 7,467 RMB/QALY; Western medicine alone was dominated. At a willingness-to-pay (WTP) threshold of 85,698 RMB/QALY (1x China’s per-capita GDP), the probability that combined therapy was cost-effective was 98.5% in probabilistic sensitivity analysis (400 iterations). Conclusions: The DES model was useful for the health-economic evaluation of TCM in COPD. The 0.060 QALY gain associated with combined therapy corresponds to approximately 22 days in full health and falls within the reported minimum clinically important difference (MCID) range for COPD (0.03–0.07 QALY), suggesting that the benefit may be clinically perceptible at the group level; individual-level variation nonetheless warrants caution. These exploratory findings, which carry potential overfitting risk given the single-trial design, require validation in larger, geographically diverse multi-center studies.
1

17 June 2023
Verified
Book Chapter
Closed access
PDF file
HHHua He
Hua He
MXMing-Yu Xu
Ming-Yu Xu
FLFei Li
Fei Li
YZYang Zhao
Yang Zhao
JWJia-Jia Wang
Jia-Jia Wang
JMjie ma
jie ma